A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)

Trial Profile

A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 May 2017

At a glance

  • Drugs Indusatumab vedotin (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Feb 2017 Results of interim analysis at the end of stage 1 of the trial published in the Investigational New Drugs.
    • 20 Apr 2016 Interim results (n=36) presented at the 107th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top